HUP0200403A3 - Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use - Google Patents
Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0200403A3 HUP0200403A3 HU0200403A HUP0200403A HUP0200403A3 HU P0200403 A3 HUP0200403 A3 HU P0200403A3 HU 0200403 A HU0200403 A HU 0200403A HU P0200403 A HUP0200403 A HU P0200403A HU P0200403 A3 HUP0200403 A3 HU P0200403A3
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolopyrimidines
- pharmaceutical compositions
- compositions containing
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10083298P | 1998-09-18 | 1998-09-18 | |
| US10083498P | 1998-09-18 | 1998-09-18 | |
| US10083398P | 1998-09-18 | 1998-09-18 | |
| US10094698P | 1998-09-18 | 1998-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200403A2 HUP0200403A2 (en) | 2002-06-29 |
| HUP0200403A3 true HUP0200403A3 (en) | 2004-07-28 |
Family
ID=27493158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200403A HUP0200403A3 (en) | 1998-09-18 | 1999-09-17 | Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1114053A1 (en) |
| JP (1) | JP2002526500A (en) |
| KR (1) | KR20010085824A (en) |
| CN (1) | CN1335849A (en) |
| AU (1) | AU753555C (en) |
| BG (1) | BG105346A (en) |
| BR (1) | BR9913887A (en) |
| CA (1) | CA2344249A1 (en) |
| CZ (1) | CZ2001960A3 (en) |
| HK (1) | HK1039326A1 (en) |
| HU (1) | HUP0200403A3 (en) |
| ID (1) | ID29028A (en) |
| IL (1) | IL141866A0 (en) |
| NO (1) | NO20011356L (en) |
| NZ (1) | NZ510588A (en) |
| PL (1) | PL346700A1 (en) |
| SK (1) | SK3842001A3 (en) |
| TR (1) | TR200101186T2 (en) |
| WO (1) | WO2000017203A1 (en) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
| ES2270612T3 (en) | 1998-08-29 | 2007-04-01 | Astrazeneca Ab | PIRIMIDINE COMPOUNDS. |
| WO2000012485A1 (en) | 1998-08-29 | 2000-03-09 | Astrazeneca Ab | Pyrimidine compounds |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| DZ3248A1 (en) | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | PYRROLO [2,3-D] PYRIMIDINE-BASED COMPOUNDS |
| ATE376996T1 (en) * | 2000-01-13 | 2007-11-15 | Amgen Inc | ANTIBACTERIAL AGENTS |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
| EE200200711A (en) * | 2000-06-26 | 2004-06-15 | Pfizer Products Inc. | Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| AR035885A1 (en) | 2001-05-14 | 2004-07-21 | Novartis Ag | DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (en) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Imidazolyl-substituted pyrimidine derivatives having CDK inhibitory activity |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| MXPA05001389A (en) | 2002-08-06 | 2005-04-28 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity. |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| NZ539901A (en) | 2002-11-26 | 2007-09-28 | Pfizer Prod Inc | Method of treatment of transplant rejection |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| EA009527B1 (en) | 2003-03-12 | 2008-02-28 | Пфайзер Продактс Инк. | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| AR045037A1 (en) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE. |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MXPA06005578A (en) * | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Pyrrolopyrimidine compounds useful in treatment of cancer. |
| WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| EA012873B1 (en) | 2004-04-02 | 2009-12-30 | Оси Фармасьютикалз, Инк. | 6,6-bicyclic ring substituted heterocyclic protein kinase inhibitors |
| MXPA06013805A (en) | 2004-05-27 | 2007-02-02 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives useful in cancer treatment. |
| MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| PE20060748A1 (en) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2 |
| CA2601766A1 (en) * | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| WO2006114180A1 (en) * | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Novel aza- heterocycles serving as kinase inhibitors |
| US8062838B2 (en) | 2005-09-20 | 2011-11-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| US8431695B2 (en) | 2005-11-02 | 2013-04-30 | Bayer Intellectual Property Gmbh | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| AR057960A1 (en) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | BICYCLE PROTEIN QUINASE INHIBITORS |
| US7659283B2 (en) * | 2006-02-14 | 2010-02-09 | Vertex Pharmaceuticals Incorporated | Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases |
| AU2007251282A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| BRPI0814423B1 (en) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Kinase modulating compounds and pharmaceutical composition comprising the same |
| JP4884570B2 (en) | 2008-08-20 | 2012-02-29 | ファイザー・インク | Pyrrolo [2,3-d] pyrimidine compound |
| JP5819195B2 (en) * | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Fusion ring heteroaryl kinase inhibitors |
| EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| US20120016119A1 (en) * | 2009-01-22 | 2012-01-19 | Yasunori Tsuboi | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
| JP2012519281A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP5656976B2 (en) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | Pyrrolotriazine compounds |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012120469A1 (en) * | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| EA201490265A1 (en) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | BLUTON TYROSINKINASE INHIBITORS |
| CN106243113B (en) | 2011-07-19 | 2018-12-18 | 默沙东有限责任公司 | The Imidazopyrazine of selection as BTK inhibitor |
| MX370814B (en) | 2011-09-02 | 2020-01-08 | Univ California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof. |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2013113097A1 (en) | 2012-01-31 | 2013-08-08 | Beta Pharma Canada Inc. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP6327713B2 (en) * | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | Acute myeloid leukemia treatment or recurrence inhibitor |
| KR20150061651A (en) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Modulation of ire1 |
| AU2014223548A1 (en) | 2013-02-26 | 2015-10-15 | Triact Therapeutics, Inc. | Cancer therapy |
| EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
| BR112016006978A2 (en) | 2013-09-30 | 2017-08-01 | Pharmacyclics Llc | bruton tyrosine kinase inhibitors |
| EP3067356B1 (en) * | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| CA2834528A1 (en) * | 2013-11-26 | 2015-05-26 | Pharmascience Inc. | Protein kinase inhibitors |
| EA201691302A1 (en) * | 2014-02-03 | 2017-03-31 | Кадила Хелзкэр Лимитед | NEW HETEROCYCLIC COMPOUNDS |
| LT3179991T (en) | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| CA3006966A1 (en) * | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
| SG11202102441VA (en) * | 2018-09-13 | 2021-04-29 | Kissei Pharmaceutical Co Ltd | Imidazopyridinone compound |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| CA3157681A1 (en) * | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| CN112961159B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidinopyrazole/pyrrole derivative and preparation method and application thereof |
| CN112961158B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidinopyrazole/pyrrole derivative and preparation method and application thereof |
| CN117402161A (en) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | Sulfoxide imine compound with FGFR inhibition effect, pharmaceutical composition containing sulfoxide imine compound and application of sulfoxide imine compound |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3036390A1 (en) * | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
| CA2100863A1 (en) * | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| BR9509048A (en) * | 1994-09-29 | 1998-01-06 | Novartis Ag | Pyrrole (2,3-d) pyrimidines and their use |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| CH690773A5 (en) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo (2,3-d) pyrimides and their use. |
| WO1997032879A1 (en) * | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES |
| CA2249739A1 (en) * | 1996-03-15 | 1997-09-25 | Novartis Ag | Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use |
| SK125999A3 (en) * | 1997-03-19 | 2000-05-16 | Knoll Ag | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
-
1999
- 1999-09-17 PL PL99346700A patent/PL346700A1/en unknown
- 1999-09-17 CA CA002344249A patent/CA2344249A1/en not_active Abandoned
- 1999-09-17 ID IDW20010652A patent/ID29028A/en unknown
- 1999-09-17 TR TR2001/01186T patent/TR200101186T2/en unknown
- 1999-09-17 BR BR9913887-5A patent/BR9913887A/en not_active IP Right Cessation
- 1999-09-17 IL IL14186699A patent/IL141866A0/en unknown
- 1999-09-17 SK SK384-2001A patent/SK3842001A3/en unknown
- 1999-09-17 CN CN99813217A patent/CN1335849A/en active Pending
- 1999-09-17 AU AU60484/99A patent/AU753555C/en not_active Ceased
- 1999-09-17 JP JP2000574112A patent/JP2002526500A/en active Pending
- 1999-09-17 WO PCT/US1999/021560 patent/WO2000017203A1/en not_active Application Discontinuation
- 1999-09-17 EP EP99969415A patent/EP1114053A1/en not_active Withdrawn
- 1999-09-17 KR KR1020017003532A patent/KR20010085824A/en not_active Application Discontinuation
- 1999-09-17 CZ CZ2001960A patent/CZ2001960A3/en unknown
- 1999-09-17 NZ NZ510588A patent/NZ510588A/en unknown
- 1999-09-17 HU HU0200403A patent/HUP0200403A3/en unknown
-
2001
- 2001-03-15 BG BG105346A patent/BG105346A/en unknown
- 2001-03-16 NO NO20011356A patent/NO20011356L/en not_active Application Discontinuation
-
2002
- 2002-01-11 HK HK02100227.3A patent/HK1039326A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL141866A0 (en) | 2002-03-10 |
| JP2002526500A (en) | 2002-08-20 |
| AU753555B2 (en) | 2002-10-24 |
| NZ510588A (en) | 2003-08-29 |
| ID29028A (en) | 2001-07-26 |
| KR20010085824A (en) | 2001-09-07 |
| BG105346A (en) | 2001-12-29 |
| CZ2001960A3 (en) | 2001-10-17 |
| BR9913887A (en) | 2001-10-23 |
| NO20011356D0 (en) | 2001-03-16 |
| CA2344249A1 (en) | 2000-03-30 |
| AU6048499A (en) | 2000-04-10 |
| WO2000017203A1 (en) | 2000-03-30 |
| EP1114053A1 (en) | 2001-07-11 |
| SK3842001A3 (en) | 2002-04-04 |
| HUP0200403A2 (en) | 2002-06-29 |
| AU753555C (en) | 2003-07-03 |
| TR200101186T2 (en) | 2001-10-22 |
| CN1335849A (en) | 2002-02-13 |
| HK1039326A1 (en) | 2002-04-19 |
| NO20011356L (en) | 2001-05-16 |
| PL346700A1 (en) | 2002-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0200403A3 (en) | Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0200355A2 (en) | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0202897A3 (en) | Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them | |
| HUP0103520A3 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them | |
| IL193615A0 (en) | New azaindoles for inhibiting protein kinases and pharmaceutical composition comprising the same | |
| HUP0202682A3 (en) | Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0202708A3 (en) | Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0400908A3 (en) | Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them | |
| HUP0103617A2 (en) | Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use | |
| HUP0400784A3 (en) | Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them | |
| HUP0103633A2 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors, process for preparation the compounds and pharmaceutical compositions containing the same | |
| HUP0202490A3 (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
| HUP0203323A3 (en) | Tyrosine kinase inhibitors and pharmaceutical compositions containing them | |
| HUP0103884A3 (en) | Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use | |
| HUP0301722A3 (en) | Pyrimidine derivatives, pharmaceutical compositions containing them and their use | |
| HUP0204514A3 (en) | Pyridinylimidazoles, pharmaceutical compositions containing them and their use | |
| HUP0200714A3 (en) | Pharmaceutical compounds, pharmaceutical compositions containing them and their use | |
| AU2728201A (en) | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | |
| IL138280A0 (en) | 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF | |
| HUP0301573A3 (en) | Substituted arylpyrazines, pharmaceutical compositions containing them and their use | |
| HUP0203325A3 (en) | Bicyclic amino acids, pharmaceutical compositions containing them and their use | |
| HUP0300318A3 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use | |
| HUP0204081A3 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
| AU2001270260A1 (en) | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | |
| HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |